Engineered immune cells take aim at Tough-to-Treat blood cancers
NCT ID NCT04007029
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial is testing a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells. It is for people with certain B-cell lymphomas or chronic lymphocytic leukemia that have come back or not responded to standard treatments. The therapy involves modifying a patient's own immune cells to better recognize and attack the cancer, combined with chemotherapy. The main goals are to check safety and find the best dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD19/CD20 bispecific CAR-T cells
- What this could lead to
- If successful, this could offer a new treatment option for patients with hard-to-treat B-cell cancers that have not responded to standard therapies.
- What could go wrong
- This is a very early (phase 1) trial with only 24 participants, so it is primarily testing safety and dosing. The treatment may not work for everyone, and side effects like cytokine release syndrome are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CD19 POSITIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Multi-Drug combo outsmart resistant lymphoma?
- Could adjusting chemo doses boost CAR T-Cell success against tough lymphoma?
- Radiation boost may supercharge CAR T-Cell therapy against tough lymphoma
- Engineered immune cells take aim at tough childhood leukemia
- Combination therapy aims to outsmart tough lymphoma
- Targeted drug combo aims to tackle Hard-to-Treat lymphoma